- Home
- GALT vs DSM Comparison
GALT vs DSM Comparison
Compare GALT & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.45
Company Overview
Basic Information| Metric | GALT | DSM |
|---|---|---|
| Founded | 2000 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 298.5M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | DSM |
|---|---|---|
| Price | $3.45 | $5.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 528.1K | 134.5K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $5.52 |
| 52 Week High | $7.13 | $6.30 |
Technical Indicators
Market Signals| Indicator | GALT | DSM |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 38.76 |
| Support Level | $2.75 | $5.80 |
| Resistance Level | $3.35 | $6.21 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 28.78 | 35.09 |
Price Performance
Historical Comparison GALT
DSM
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.